AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8059811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2648511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isoniazid, rifampicin, and pyrazinamide (fixed proportions)
Number of subjects: 250
Study 2648511 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of isoniazid, rifampicin, and pyrazinamide
Number of subjects: 250
Study 5338884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 4‐5360, 10 mg. (Mogadon)
Number of subjects: 0
Study 5338884 — intervention group
Group type: EXPERIMENTAL
Intervention: methyprylon, 200 mg. (Noludar)
Number of subjects: 0
Study 5338884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 4‐5360, 5 mg. (Mogadon)
Number of subjects: 0
Study 5338884 — intervention group
Group type: EXPERIMENTAL
Intervention: secobarbital sodium, 100 mg. (Seconal)
Number of subjects: 0
Study 5338884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30939905 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise programme
Number of subjects: 137
Study 30939905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study 28455295 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stroke volume indexed for body surface area (SVI) defined as <35 mL/m2
Number of subjects: 1671
Study 28455295 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SVI
Number of subjects: 1671
Study 28455295 — intervention group
Group type: EXPERIMENTAL
Intervention: In-study low SVI
Number of subjects: 1671
Study 25974325 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary orchiopexy
Number of subjects: 112
Study 25974325 — intervention group
Group type: COMPARATOR
Intervention: Two-stage orchiopexy
Number of subjects: 112
Study 23716516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration (drank 250 mL of water at 15‐minute intervals, totaling 1000 mL/h)
Number of subjects: 79
Study 23716516 — intervention group
Group type: COMPARATOR
Intervention: Control (no hydration)
Number of subjects: 79
Study 21494161 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 16
Study 21494161 — intervention group
Group type: COMPARATOR
Intervention: Miller
Number of subjects: 16
Study 18356517 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming with the concept of exertion
Number of subjects: 0
Study 18356517 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal primes accompanied by consciously visible positive stimuli
Number of subjects: 0
Study 16779972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied to experimental dental quadrants every 3 months during 12 months of orthodontic treatment
Number of subjects: 10
Study 16779972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 10
Study 14699594 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) treatment for one or two consecutive sessions
Number of subjects: 17
Study 14699594 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) treatment
Number of subjects: 17
Study 10898125 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hr sleep deprivation
Number of subjects: 28
Study 10898125 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep periods (NSP)
Number of subjects: 28
Study 9360001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg reserpine plus 5 mg clopamide (R/C)
Number of subjects: 127
Study 9360001 — intervention group
Group type: COMPARATOR
Intervention: 5 mg enalapril
Number of subjects: 127
Study 1541966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal corticosteroids
Number of subjects: 50
Study 1541966 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids
Number of subjects: 50
Study 2879292 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich diet
Number of subjects: 0
Study 2879292 — intervention group
Group type: COMPARATOR
Intervention: LA-rich diet
Number of subjects: 0
Study 2879292 — intervention group
Group type: COMPARATOR
Intervention: LNA-rich diet
Number of subjects: 0
Study 30417575 — intervention group
Group type: EXPERIMENTAL
Intervention: TAKE 5 multi-component weight management programme including an energy deficit diet (EDD)
Number of subjects: 0
Study 30417575 — intervention group
Group type: COMPARATOR
Intervention: Waist Winners Too based on health education principles
Number of subjects: 0
Study 29856470 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrecizumab (various doses)
Number of subjects: 48
Study 29856470 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrecizumab (1 ng kg-1 h-1) during endotoxaemia
Number of subjects: 48
Study 29856470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26666481 — intervention group
Group type: EXPERIMENTAL
Intervention: High TEWL group (TEWL > 6.5 g/m(2)/h)
Number of subjects: 116
Study 26666481 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily emollient use in high TEWL group
Number of subjects: 116
Study 26666481 — intervention group
Group type: EXPERIMENTAL
Intervention: High TEWL group
Number of subjects: 116
Study 26666481 — intervention group
Group type: COMPARATOR
Intervention: Low TEWL group
Number of subjects: 116
Study 24657685 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18140
Study 24657685 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18140
Study 22823856 — intervention group
Group type: EXPERIMENTAL
Intervention: Child plus parent intervention
Number of subjects: 88
Study 22823856 — intervention group
Group type: COMPARATOR
Intervention: Child only intervention
Number of subjects: 88
Study 18005310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of irrigation before harvesting
Number of subjects: 726
Study 15615797 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 36
Study 15615797 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (no-PCI)
Number of subjects: 36
Study 14969077 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg once a week
Number of subjects: 0
Study 14969077 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 0
Study 14969077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 10382902 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human G‐CSF (rhG‐CSF)
Number of subjects: 40
Study 10382902 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin and amphotericin B (CAB)
Number of subjects: 40
Study 10382902 — intervention group
Group type: EXPERIMENTAL
Intervention: Median hospitalization duration and costs
Number of subjects: 40
Study 10382902 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 40
Study 10382902 — intervention group
Group type: COMPARATOR
Intervention: prophylactic CAB
Number of subjects: 40
Study 8886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 1,000 mg once daily
Number of subjects: 347
Study 8886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg BID
Number of subjects: 347
Study 8886213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 8886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 1,000 mg once daily (open-label phase)
Number of subjects: 347
Study 8886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg BID (open-label phase)
Number of subjects: 347
Study 8886213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (open-label phase)
Number of subjects: 347
Study 1999025 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 686
Study 1999025 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 686
Study 6360747 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0
Study 6360747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31342907 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CuidateChemo (Web-based exercise program)
Number of subjects: 68
Study 29126178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic pedaling exercise (EX)
Number of subjects: 20
Study 29126178 — intervention group
Group type: COMPARATOR
Intervention: Usual hemodialysis (nonEX)
Number of subjects: 20
Study 27317505 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-specific treatment (CS)
Number of subjects: 101
Study 27317505 — intervention group
Group type: COMPARATOR
Intervention: Non classification-specific treatment (NCs)
Number of subjects: 101
Study 27317505 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance training adherence
Number of subjects: 101
Study 27317505 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise adherence
Number of subjects: 101
Study 25288615 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental drinking (either parent drank)
Number of subjects: 2200
Study 25288615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both parents drank
Number of subjects: 2200
Study 25288615 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional drinking fathers
Number of subjects: 2200
Study 25288615 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent drinking fathers
Number of subjects: 2200
Study 25288615 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional drinking mothers
Number of subjects: 2200
Study 25288615 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent drinking mothers
Number of subjects: 2200
Study 25288615 — intervention group
Group type: COMPARATOR
Intervention: Non-drinking parents
Number of subjects: 2200
Study 22522759 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological crisis intervention
Number of subjects: 107
Study 22522759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 107
Study 20025989 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three days a week for 6 months
Number of subjects: 22
Study 20025989 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 22
Study 20025989 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 22
Study 18082517 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3910
Study 18082517 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3910
Study 18082517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Enoxaparin and UFH
Number of subjects: 3910
Study 15572589 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1343
Study 15572589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for cardiovascular risk factors and morbidity
Number of subjects: 1343
Study 15572589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for cardiovascular morbidity
Number of subjects: 1343
Study 15572589 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 51 men and 45 women with low risk profile and no cardiovascular morbidity
Number of subjects: 1343
Study 12492726 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg single dose
Number of subjects: 0
Study 12492726 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg once daily for 7 days
Number of subjects: 0
Study 12492726 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine
Number of subjects: 0
Study 12492726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9618124 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (4,186 kJ/day to 5,023 kJ/day)
Number of subjects: 80
Study 9618124 — intervention group
Group type: COMPARATOR
Intervention: Dietary fat restriction (22 g/day to 26 g/day)
Number of subjects: 80
Study 7623005 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of hepatitis A antigen per dose)
Number of subjects: 46
Study 7623005 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 46
Study 7623005 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated (control)
Number of subjects: 46
Study 2646089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 24
Study 2646089 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 24
Study 2646089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 207210 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP (trimethroprim‐sulphacetamide‐polomyxin B) ear drops
Number of subjects: 100
Study 207210 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (Garamycine) ear drops
Number of subjects: 100
Study 207210 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 100
Study 207210 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP
Number of subjects: 100
Study 31238927 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual education
Number of subjects: 39
Study 31238927 — intervention group
Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 39
Study 28957563 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2
Number of subjects: 584
Study 28957563 — intervention group
Group type: COMPARATOR
Intervention: INF
Number of subjects: 584
Study 26251107 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal caregivers (SCs)
Number of subjects: 236
Study 26251107 — intervention group
Group type: COMPARATOR
Intervention: Nonspousal caregivers (NSCs)
Number of subjects: 236
Study 26251107 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed spousal caregivers
Number of subjects: 236
Study 26251107 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' depressive symptoms
Number of subjects: 236
Study 22963594 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect and self-affirmation (PA/SA) intervention
Number of subjects: 756
Study 22963594 — intervention group
Group type: COMPARATOR
Intervention: Informational control
Number of subjects: 756
Study 21324929 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE intervention (practising with the anaesthesia mask at home and parental planning and use of distraction)
Number of subjects: 96
Study 21324929 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE intervention (mask practice and distraction)
Number of subjects: 96
Study 19188372 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign to increase awareness and use of condoms
Number of subjects: 0
Study 19188372 — intervention group
Group type: COMPARATOR
Intervention: Precampaign data
Number of subjects: 0
Study 19188372 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcampaign data
Number of subjects: 0
Study 16452558 — intervention group
Group type: COMPARATOR
Intervention: BIG‐IV
Number of subjects: 122
Study 16452558 — intervention group
Group type: EXPERIMENTAL
Intervention: BIG‐IV (within seven days of admission)
Number of subjects: 122
Study 14971532 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day of Pueraria mirifica (Group A)
Number of subjects: 37
Study 14971532 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of Pueraria mirifica (Group B)
Number of subjects: 37
Study 14971532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (both doses)
Number of subjects: 37
Study 11146522 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical correction of the dilated PA
Number of subjects: 12
Study 9469523 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg orally)
Number of subjects: 24
Study 9469523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8195389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed inoculum of cold-adapted and wild-type viruses
Number of subjects: 0
Study 8195389 — intervention group
Group type: COMPARATOR
Intervention: Wild-type A/Kawasaki virus
Number of subjects: 0
Study 8195389 — intervention group
Group type: COMPARATOR
Intervention: Cold-adapted virus only
Number of subjects: 0
Study 2821080 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg twice daily, maximum dose = 40 mg/d)
Number of subjects: 150
Study 2821080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg twice daily, maximum dose = 400 mg/d)
Number of subjects: 150
Study 2821080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 150
Study 2821080 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 150
Study 2821080 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and Metoprolol
Number of subjects: 150
Study 31453961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg daily
Number of subjects: 631
Study 31453961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 29042000 — intervention group
Group type: EXPERIMENTAL
Intervention: NBR biofeedback
Number of subjects: 33
Study 29042000 — intervention group
Group type: EXPERIMENTAL
Intervention: NBR biofeedback plus topiramate 50 mg (b.i.d.)
Number of subjects: 33
Study 29042000 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg (b.i.d.)
Number of subjects: 33
Study 26178748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor (NGF) injection into extensor carpi radialis brevis (ECRB) muscle
Number of subjects: 26
Study 26178748 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection into extensor carpi radialis brevis (ECRB) muscle
Number of subjects: 26
Study 24014143 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-1000 kcal meal (Study 1)
Number of subjects: 42
Study 24014143 — intervention group
Group type: COMPARATOR
Intervention: Fasted state (Study 1)
Number of subjects: 42
Study 24014143 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 kcal/high-fat meal (Study 2)
Number of subjects: 42
Study 24014143 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 kcal/high-fat meal (Study 2)
Number of subjects: 42
Study 24014143 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-1000 kcal/high-fat meal (Study 2)
Number of subjects: 42
Study 24014143 — intervention group
Group type: COMPARATOR
Intervention: Fasted state (Study 2)
Number of subjects: 42
Study 21166786 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 165
Study 21166786 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 165
Study 17991805 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement therapy for SCTD; specific dosage and duration not mentioned.
Number of subjects: 0
Study 17991805 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; no specific intervention mentioned for control.
Number of subjects: 0
Study 16259942 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal therapy (HR)
Number of subjects: 30
Study 16259942 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 30
Study 15097950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined examination with mandatory excision of equivocal lesions (arm B)
Number of subjects: 913
Study 15097950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined examination with possibility of digital follow‐up according to clinician's decision (arm C)
Number of subjects: 913
Study 15097950 — intervention group
Group type: COMPARATOR
Intervention: Conventional naked‐eye examination (mandatory excision of equivocal lesions) (arm A)
Number of subjects: 913
Study 11329490 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP) 10-15 mg/kg p.o.
Number of subjects: 0
Study 11329490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11329490 — intervention group
Group type: COMPARATOR
Intervention: Lingonberry juice (no ethanol or methanol)
Number of subjects: 0
Study 9141607 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-applied transtelephonic device (WrTTD)
Number of subjects: 24
Study 9141607 — intervention group
Group type: COMPARATOR
Intervention: Precordial transtelephonic device (PrTTD)
Number of subjects: 24
Study 7962671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol hemifumarate (5 to 40 mg)
Number of subjects: 8
Study 2891536 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oxmetidine
Number of subjects: 12
Study 2891536 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oxmetidine
Number of subjects: 12
Study 2891536 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ranitidine
Number of subjects: 12
Study 2891536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30543668 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront point-of-care (POC) testing
Number of subjects: 28
Study 30543668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of 3 or more tests
Number of subjects: 28
Study 30543668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations with 2 or less tests
Number of subjects: 28
Study 30543668 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive blood results included in combinations
Number of subjects: 28
Study 27530135 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-caliber coils
Number of subjects: 564
Study 27530135 — intervention group
Group type: COMPARATOR
Intervention: 10-caliber coils
Number of subjects: 564
Study 23703687 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychosocial assessment
Number of subjects: 10
Study 23703687 — intervention group
Group type: COMPARATOR
Intervention: Interview-based psychosocial assessment
Number of subjects: 10
Study 22314016 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation intervention
Number of subjects: 16430
Study 20127563 — intervention group
Group type: EXPERIMENTAL
Intervention: XL-184 (BMS-907351)
Number of subjects: 0
Study 18998925 — intervention group
Group type: EXPERIMENTAL
Intervention: CTeXplorer tool for visualizing design heterogeneity in clinical trials
Number of subjects: 12
Study 12494305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling on protein restriction (n=63)
Number of subjects: 131
Study 12494305 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice (Control group, n=68)
Number of subjects: 131
Study 9735677 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0